These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 38710868

  • 1. Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study.
    Tesfaye H, Wang KM, Zabotka LE, Wexler DJ, Schmedt N, Koeneman L, Seman L, Paik JM, Patorno E.
    J Gen Intern Med; 2024 Aug; 39(10):1870-1879. PubMed ID: 38710868
    [Abstract] [Full Text] [Related]

  • 2. Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes.
    Tesfaye H, Paik JM, Roh M, Htoo PT, Zakoul H, Schmedt N, Koeneman L, Wexler DJ, Patorno E.
    JAMA Ophthalmol; 2024 Dec 05. PubMed ID: 39636645
    [Abstract] [Full Text] [Related]

  • 3. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.
    Fu EL, Wexler DJ, Cromer SJ, Bykov K, Paik JM, Patorno E.
    BMJ; 2024 Jun 26; 385():e078483. PubMed ID: 38925801
    [Abstract] [Full Text] [Related]

  • 4. SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum.
    Preston FG, Anson M, Riley DR, Ibarburu GH, Henney A, Lip GYH, Cuthbertson DJ, Alam U, Zhao SS.
    Clin Ther; 2024 Nov 26; 46(11):835-840. PubMed ID: 39068059
    [Abstract] [Full Text] [Related]

  • 5. Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes.
    Htoo PT, NajafZadeh M, Tesfaye H, Schneeweiss S, Wexler DJ, Glynn RJ, Schmedt N, Déruaz-Luyet A, Koeneman L, Paik JM, Patorno E.
    Diabetes Care; 2024 Nov 01; 47(11):1900-1907. PubMed ID: 38917305
    [Abstract] [Full Text] [Related]

  • 6. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y.
    Adv Ther; 2019 Oct 01; 36(10):2567-2586. PubMed ID: 31444707
    [Abstract] [Full Text] [Related]

  • 7. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD.
    JAMA Cardiol; 2021 Jul 01; 6(7):801-810. PubMed ID: 33851953
    [Abstract] [Full Text] [Related]

  • 8. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC, Chen CW, Yen HK, Lin YP, Lai CY, Wang JL, Groot OQ, Janssen SJ, Schwab JH, Hsu FM, Lin WH.
    Clin Orthop Relat Res; 2024 Dec 01; 482(12):2193-2208. PubMed ID: 39051924
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands.
    Slob B, Fens T, Weersma M, Postma M, Boersma C, de Jong L.
    PLoS One; 2024 Dec 01; 19(12):e0315509. PubMed ID: 39656735
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
    Elwenspoek MM, Thom H, Sheppard AL, Keeney E, O'Donnell R, Jackson J, Roadevin C, Dawson S, Lane D, Stubbs J, Everitt H, Watson JC, Hay AD, Gillett P, Robins G, Jones HE, Mallett S, Whiting PF.
    Health Technol Assess; 2022 Oct 01; 26(44):1-310. PubMed ID: 36321689
    [Abstract] [Full Text] [Related]

  • 15. Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
    Doehner W, Anker SD, Butler J, Zannad F, Filippatos G, Coats AJS, Ferreira JP, Henrichmoeller I, Brueckmann M, Schueler E, Pocock SJ, Januzzi JL, Packer M.
    JACC Heart Fail; 2024 Dec 01; 12(12):2057-2070. PubMed ID: 39453357
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Neuen BL, Fletcher RA, Heath L, Perkovic A, Vaduganathan M, Badve SV, Tuttle KR, Pratley R, Gerstein HC, Perkovic V, Heerspink HJL.
    Circulation; 2024 Nov 26; 150(22):1781-1790. PubMed ID: 39210781
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians.
    Qaseem A, Obley AJ, Shamliyan T, Hicks LA, Harrod CS, Crandall CJ, Clinical Guidelines Committee of the American College of Physicians, Balk EM, Cooney TG, Cross JT, Fitterman N, Lin JS, Maroto M, Miller MC, Shekelle P, Tice JA, Tufte JE, Etxeandia-Ikobaltzeta I, Yost J.
    Ann Intern Med; 2024 May 26; 177(5):658-666. PubMed ID: 38639546
    [No Abstract] [Full Text] [Related]

  • 20. Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP-4i) in US Adults with Type 2 Diabetes.
    Tan X, Liang Y, Gamble C, King A.
    Diabetes Ther; 2024 Feb 26; 15(2):427-445. PubMed ID: 38060149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.